Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95
Published on 10/13/2026 at 08:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Regeneron reported positive 84-week Phase 3 OPTIMA results for Pasatru.
- No new HO lesions were observed at week 84 for Pasatru from week 56.
- The stock was at EUR 684.95 pre-market at Lang & Schwarz on October 13, 2026.
Pre-market indication
Lang & Schwarz showed a bid of EUR 681.60 and an ask of EUR 688.30. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Regeneron stock.
Pasatru trial update
According to the issuer-authored release on GlobeNewswire, no new heterotopic ossification lesions were observed at week 84 from week 56 among participants receiving Pasatru, compared with nine new lesions for placebo. The release said the data were presented during a late-breaking session at the American Society for Bone and Mineral Research annual meeting.
Study details
The OPTIMA trial enrolled 63 adults, who received Pasatru at 10 mg/kg, Pasatru at 3 mg/kg, or placebo once every four weeks for 56 weeks. The release said 58 participants completed the double-blind extension phase to at least 84 weeks. New clinician-assessed flare-ups numbered one for the 10 mg/kg group, 14 for the 3 mg/kg group and 17 for placebo.
Market context: Market report S&P 500.
